CAJ | 학술논문

进展期胃癌的治疗模式目前主要是以胃癌D2根治性切除手术为主的综合治疗，其中胃癌围手术期化疗已得到临床医师的广泛重视。已有多项大型临床试验证实，胃癌D2根治术后辅助化疗可显著改善患者生存，但手术前后的联合化疗和术后辅助放疗的治疗作用尚存争议。在此基础上，国内外研究者设计了多项临床试验，期望能更好地寻找目标人群，优化治疗方案。同时，对于胃癌分子标志物的深入研究和基于胃癌基因图谱研究结果的新分子分型的出现，将会有助于对胃癌患者进行个体化围手术期化疗方案的制订，从而尽可能地改善患者生活质量，延长生存时间。
진전기위암적치료모식목전주요시이위암D2근치성절제수술위주적종합치료，기중위암위수술기화료이득도림상의사적엄범중시。이유다항대형림상시험증실，위암D2근치술후보조화료가현저개선환자생존，단수술전후적연합화료화술후보조방료적치료작용상존쟁의。재차기출상，국내외연구자설계료다항림상시험，기망능경호지심조목표인군，우화치료방안。동시，대우위암분자표지물적심입연구화기우위암기인도보연구결과적신분자분형적출현，장회유조우대위암환자진행개체화위수술기화료방안적제정，종이진가능지개선환자생활질량，연장생존시간。
Recently the standard treatment for advanced gastric cancer is the multimodal therapies associated with complete surgical resection of cancer ﹙D2 dissection) and now more and more clinical attentions have been paid to chemotherapy. It has been confirmed by several randomized phase Ⅲ clinical trials that adjuvant chemotherapy after D2 dissection can significantly improve patients' survival. But it is still in debate that perioperative chemotherapy﹙adjuvant and neoadjuvant) and postoperative radiotherapy can really bring survival benefits for gastric cancer patients who received curative D2 dissections. Based on these questions, investigators designed different ongoing clinical trials in order to define subsets of patients who will more likely benefit from specific therapies and optimize the regimens and sequence. Meanwhile, along with the deep research of gastric cancer biomarkers and introduction of novel molecular subtypes of gastric cancer based on cancer genome atlas project, personalized or individual chemotherapy treatment will come into reality for improving survival and having better life quality for gastric cancer patients.